Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine** is a synthetic small molecule belonging to the phenylpiperazine class of organic compounds[2][4][5]. It has been studied primarily as an antiviral agent, notably for its ability to bind to the coat protein of human rhinovirus 14, suggesting potential as an inhibitor of viral entry or uncoating[3]. The compound is referenced in structural biology studies (PDB accession code: 1R09), where it was complexed with rhinovirus proteins. There are no known approved therapeutic indications or marketed products containing this compound. Its mechanism of action is presumed to involve interaction with viral capsid proteins, but detailed pharmacological data and clinical development status are not available in public databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine.